Direct modulation of rheumatoid inflammatory mediator expression in retinoblastoma protein–dependent and –independent pathways by cyclin-dependent kinase 4/6
Yoshinori Nonomura
Tokyo Medical and Dental University, Tokyo, and RIKEN Research Center of Allergy and Immunology, Yokohama, Japan
Drs. Nonomura and Nagasaka contributed equally to this work.
Search for more papers by this authorKenji Nagasaka
Tokyo Medical and Dental University, Tokyo, Japan
Drs. Nonomura and Nagasaka contributed equally to this work.
Search for more papers by this authorHiroyuki Hagiyama
Tokyo Medical and Dental University, Tokyo, Japan
Search for more papers by this authorChiyoko Sekine
Tokyo Medical and Dental University, Tokyo, and RIKEN Research Center of Allergy and Immunology, Yokohama, Japan
Search for more papers by this authorToshihiro Nanki
Tokyo Medical and Dental University, Tokyo, Japan
Search for more papers by this authorMimi Tamamori-Adachi
Tokyo Medical and Dental University, Tokyo, Japan
Search for more papers by this authorNobuyuki Miyasaka
Tokyo Medical and Dental University, Tokyo, Japan
Search for more papers by this authorCorresponding Author
Hitoshi Kohsaka
Tokyo Medical and Dental University, Tokyo, and RIKEN Research Center of Allergy and Immunology, Yokohama, Japan
Department of Medicine and Rheumatology, Graduate School, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, 113-8519 Tokyo, JapanSearch for more papers by this authorYoshinori Nonomura
Tokyo Medical and Dental University, Tokyo, and RIKEN Research Center of Allergy and Immunology, Yokohama, Japan
Drs. Nonomura and Nagasaka contributed equally to this work.
Search for more papers by this authorKenji Nagasaka
Tokyo Medical and Dental University, Tokyo, Japan
Drs. Nonomura and Nagasaka contributed equally to this work.
Search for more papers by this authorHiroyuki Hagiyama
Tokyo Medical and Dental University, Tokyo, Japan
Search for more papers by this authorChiyoko Sekine
Tokyo Medical and Dental University, Tokyo, and RIKEN Research Center of Allergy and Immunology, Yokohama, Japan
Search for more papers by this authorToshihiro Nanki
Tokyo Medical and Dental University, Tokyo, Japan
Search for more papers by this authorMimi Tamamori-Adachi
Tokyo Medical and Dental University, Tokyo, Japan
Search for more papers by this authorNobuyuki Miyasaka
Tokyo Medical and Dental University, Tokyo, Japan
Search for more papers by this authorCorresponding Author
Hitoshi Kohsaka
Tokyo Medical and Dental University, Tokyo, and RIKEN Research Center of Allergy and Immunology, Yokohama, Japan
Department of Medicine and Rheumatology, Graduate School, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, 113-8519 Tokyo, JapanSearch for more papers by this authorAbstract
Objective
It is known that the cyclin-dependent kinase inhibitor (CDKI) gene p21Cip1 suppresses rheumatoid inflammation by down-modulating type I interleukin-1 receptor (IL-1RI) expression and inhibiting JNK activity. The purpose of this study was to determine whether CDK activity directly modulates the production of inflammatory molecules in patients with rheumatoid arthritis (RA).
Methods
Genes for the CDKIs p16INK4a and p18INK4c, a constitutively active form of retinoblastoma (RB) gene product, cyclin D1, and CDK-4, were transferred into RA synovial fibroblasts (RASFs). RASFs were also treated with a synthetic CDK-4/6 inhibitor (CDK4I). Levels of matrix metalloproteinase 3 (MMP-3), monocyte chemoattractant protein 1 (MCP-1), and IL-1RI expression were determined by Northern blotting, real-time polymerase chain reaction analysis, and enzyme-linked immunosorbent assay. CDKIs were immunoprecipitated to reveal their association with JNK.
Results
Transfer of the p16INK4a and p18INK4c genes and CDK4I suppressed the production of MMP-3 and MCP-1. Unlike p21Cip1, neither CDKI gene inhibited IL-1RI or JNK. The expression of MMP-3 was up-regulated when CDK-4 activity was augmented. This regulation functioned at the messenger RNA (mRNA) level in MMP-3, but not in MCP-1. Transfer of active RB suppressed the production of MMP-3 and MCP-1 without changing their mRNA levels.
Conclusion
CDK-4/6 modulated the production of MMP-3 and MCP-1. MMP-3 production was regulated primarily at the mRNA level in an RB-independent manner, whereas MCP-1 production was controlled posttranscriptionally by RB. These results show that cell cycle proteins are associated with control of mediators of inflammation through multiple pathways.
REFERENCES
- 1 Arend WP. Physiology of cytokine pathways in rheumatoid arthritis. Arthritis Rheum 2001; 45: 101–6.
- 2 Bresnihan B. Pathogenesis of joint damage in rheumatoid arthritis. J Rheumatol 1999; 26: 17–719.
- 3 Andreakos E, Foxwell B, Brennan F, Maini R, Feldmann M. Cytokines and anti-cytokine biologicals in autoimmunity: present and future. Cytokine Growth Factor Rev 2002; 13: 299–313.
- 4 Taniguchi K, Kohsaka H, Inoue N, Terada Y, Ito H, Hirokawa K, et al. Induction of the p16INK4a senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritis. Nat Med 1999; 5: 760–7.
- 5 Nasu K, Kohsaka H, Nonomura Y, Terada Y, Ito H, Hirokawa K, et al. Adenoviral transfer of cyclin-dependent kinase inhibitor genes suppresses collagen-induced arthritis in mice. J Immunol 2000; 165: 7246–52.
- 6 Nonomura Y, Kohsaka H, Nasu K, Terada Y, Ikeda M, Miyasaka N. Suppression of arthritis by forced expression of cyclin-dependent kinase inhibitor p21Cip1 gene into the joints. Int Immunol 2001; 13: 723–31.
- 7 Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501–12.
- 8 Nonomura Y, Kohsaka H, Nagasaka K, Miyasaka N. Gene transfer of a cell cycle modulator exerts anti-inflammatory effects in the treatment of arthritis. J Immunol 2003; 171: 4913–19.
- 9 Shim J, Lee H, Park J, Kim H, Choi EJ. A non-enzymatic p21 protein inhibitor of stress-activated protein kinases. Nature 1996; 381: 804–6.
- 10 Perlman H, Bradley K, Liu H, Cole S, Shamiyeh E, Smith RC, et al. IL-6 and matrix metalloproteinase-1 are regulated by the cyclin-dependent kinase inhibitor p21 in synovial fibroblasts. J Immunol 2003; 170: 838–45.
- 11 Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24.
- 12 Terada Y, Yamada T, Nakashima O, Tamamori M, Ito H, Sasaki S, et al. Overexpression of cell cycle inhibitors (p16INK4a and p21Cip1) and cyclin D1 using adenovirus vectors regulates proliferation of rat mesangial cells. J Am Soc Nephrol 1997; 8: 51–60.
- 13 Blais A, Labrie Y, Pouliot F, Lachance Y, Labrie C. Structure of the gene encoding the human cyclin-dependent kinase inhibitor p18 and mutational analysis in breast cancer. Biochem Biophys Res Commun 1998; 247: 146–53.
- 14 Mizuguchi H, Kay MA. A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. Hum Gene Ther 1999; 10: 2013–7.
- 15 Mizuguchi H, Kay MA. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum Gene Ther 1998; 9: 2577–83.
- 16 Tamamori-Adachi M, Ito H, Nobori K, Hayashida K, Kawauchi J, Adachi S, et al. Expression of cyclin D1 and CDK4 causes hypertrophic growth of cardiomyocytes in culture: a possible implication for cardiac hypertrophy. Biochem Biophys Res Commun 2002; 296: 274–80.
- 17 Tamamori-Adachi M, Ito H, Sumrejkanchanakij P, Adachi S, Hiroe M, Shimizu M, et al. Critical role of cyclin D1 nuclear import in cardiomyocyte proliferation. Circ Res 2003; 92: e12–9.
- 18 Chang MW, Barr E, Seltzer J, Jiang YQ, Nabel GJ, Nabel EG, et al. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 1995; 267: 518–22.
- 19 Terao R, Honda K, Hatano E, Uehara T, Yamamoto M, Yamaoka Y. Suppression of proliferative cholangitis in a rat model with direct adenovirus-mediated retinoblastoma gene transfer to the biliary tract. Hepatology 1998; 28: 605–12.
- 20 Mizuguchi H, Koizumi N, Hosono T, Utoguchi N, Watanabe Y, Kay MA, et al. A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. Gene Ther 2001; 8: 730–5.
- 21 Inoue H, Takamori M, Nagata N, Nishikawa T, Oda H, Yamamoto S, et al. An investigation of cell proliferation and soluble mediators induced by interleukin 1β in human synovial fibroblasts: comparative response in osteoarthritis and rheumatoid arthritis. Inflamm Res 2001; 50: 65–72.
- 22 Elshaw SR, Henderson N, Knox AJ, Watson SA, Buttle DJ, Johnson SR. Matrix metalloproteinase expression and activity in human airway smooth muscle cells. Br J Pharmacol 2004; 142: 1318–24.
- 23 Pierer M, Rethage J, Seibl R, Lauener R, Brentano F, Wagner U, et al. Chemokine secretion of rheumatoid arthritis synovial fibroblasts stimulated by Toll-like receptor 2 ligands. J Immunol 2004; 172: 1256–65.
- 24 Zhong H, Simons JW. Direct comparison of GAPDH, β-actin, cyclophilin, and 28S rRNA as internal standards for quantifying RNA levels under hypoxia. Biochem Biophys Res Commun 1999; 259: 523–26.
- 25 Zhu G, Conner SE, Zhou X, Shih C, Li T, Anderson BD, et al. Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors. J Med Chem 2003; 46: 2027–30.
- 26 Patel R, Bartosch B, Blank JL. p21WAF1 is dynamically associated with JNK in human T-lymphocytes during cell cycle progression. J Cell Sci 1998; 111: 2247–55.
- 27 Bradley K, Scatizzi JC, Fiore S, Shamiyeh E, Koch AE, Firestein GS, et al. Retinoblastoma suppression of matrix metalloproteinase 1, but not interleukin-6, through a p38-dependent pathway in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2004; 50: 78–87.
- 28 Okada Y. Proteinases and matrix degradation. In: S Ruddy, ED Harris, CB Sledge, RC Budd, JS Sergent, editors. Kelley's textbook of rheumatology. 6th ed. Philadelphia: WB Saunders; 2001. p. 55–72.
- 29 Tolboom TC, Pieterman E, van der Laan WH, Toes RE, Huidekoper AL, Nelissen RG, et al. Invasive properties of fibroblast-like synoviocytes: correlation with growth characteristics and expression of MMP-1, MMP-3, and MMP-10. Ann Rheum Dis 2002; 61: 975–80.
- 30 Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 1997; 378: 151–60.
- 31 Van Meurs J, van Lent P, Stoop R, Holthuysen A, Singer I, Bayne E, et al. Cleavage of aggrecan at the Asn341-Phe342 site coincides with the initiation of collagen damage in murine antigen-induced arthritis: a pivotal role for stromelysin 1 in matrix metalloproteinase activity. Arthritis Rheum 1999; 42: 2074–84.
- 32 Hamada T, Arima N, Shindo M, Sugama K, Sasaguri Y, Brewster M, et al. Suppression of adjuvant arthritis of rats by a novel matrix metalloproteinase-inhibitor Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis. Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. Br J Pharmacol 2000; 131: 1513–20.
- 33 Ishikawa T, Nishigaki F, Miyata S, Hirayama Y, Minoura K, Imanishi J, et al. Prevention of progressive joint destruction in adjuvant induced arthritis in rats by a novel matrix metalloproteinase inhibitor, FR217840: suppression of adjuvant arthritis of rats by a novel matrix metalloproteinase-inhibitor. Eur J Pharmacol 2005; 508: 239–47.
- 34 Lewis EJ, Bishop J, Bottomley KM, Bradshaw D, Brewster M, Broadhurst MJ, et al. Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. Br J Pharmacol 1997; 121: 540–6.
- 35 Koch AE, Kunkel SL, Harlow LA, Johnson B, Evanoff HL, Haines GK, et al. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest 1992; 90: 772–9.
- 36 Gong JH, Ratkay LG, Waterfield JD, Clark-Lewis I. An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. J Exp Med 1997; 186: 131–7.
- 37 Wolff B, Naumann M. INK4 cell cycle inhibitors direct transcriptional inactivation of NF-κB. Oncogene 1999; 18: 2663–6.
- 38 Wasylyk C, Gutman A, Nicholson R, Wasylyk B. The c-Ets oncoprotein activates the stromelysin promoter through the same elements as several non-nuclear oncoproteins. EMBO J 1991; 10: 1127–34.
- 39 White LA, Maute C, Brinckerhoff CE. ETS sites in the promoters of the matrix metalloproteinases collagenase (MMP-1) and stromelysin (MMP-3) are auxiliary elements that regulate basal and phorbol-induced transcription. Connect Tissue Res 1997; 36: 321–35.
- 40 Senderowicz AM. Small-molecule cyclin-dependent kinase modulators. Oncogene 2003; 22: 6609–20.
